| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 | 2021-03-12 | 2025-03-31 | 2025-03-31 |
| NCT04757636 | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 | 2021-03-12 | 2025-03-31 | 2025-03-31 |
| NCT03397264 | A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema | COMPLETED | PHASE1, PHASE2 | 2018-01-16 | 2020-06-11 | 2020-03-26 |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | COMPLETED | PHASE2 | 2017-11-06 | 2019-05-14 | 2019-05-14 |
| NCT02543229 | Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD | COMPLETED | PHASE1 | 2015-07 | 2017-09 | 2017-02-07 |